Atypical Bilateral Femur Fractures in a Long-Term Bisphosphonate Therapy: A Case Report

2015 ◽  
Vol 04 (02) ◽  
Author(s):  
Roberto Valentini Alessandro Moghnie
Keyword(s):  
Case Report ◽  
Bisphosphonate Therapy ◽  
Femur Fractures

scholarly journals Atypical Femoral Fracture during Long-term Bisphosphonate Therapy: A Case Report

2012 ◽  
Vol 61 (4) ◽  
pp. 795-798
Author(s):  
Kenichi Seo ◽  
Shinji Tomari ◽  
Yasumasa Ito ◽  
Tatsuya Yufu ◽  
Takahiro Yasuhara ◽  
...  
Keyword(s):  
Case Report ◽  
Femoral Fracture ◽  
Bisphosphonate Therapy ◽  
Atypical Femoral Fracture

scholarly journals Long-term risks of bisphosphonate therapy

2014 ◽  
Vol 58 (5) ◽  
pp. 523-529 ◽  
Author(s):  
Nelson B. Watts
Keyword(s):  
Lower Risk ◽  
Observational Studies ◽  
Osteonecrosis Of The Jaw ◽  
Bisphosphonate Therapy ◽  
Safety Issues ◽  
Femur Fractures ◽  
Atypical Femur Fractures ◽  
Post Marketing ◽  
Risk Patients

The objective this study was to summarize long-term risks associated with bisphosphonate therapy. Search of relevant medical publications for data from clinical trials, trial extensions, observational studies and post-marketing reports. Trial extensions and modifications did not reveal significant long-term safety issues. Observational data suggest at least as many benefits as risks. Post-marketing reports of musculoskeletal pain, osteonecrosis of the jaw and atypical femur fractures have been widely circulated in the lay press. Most focus on long-terms risks has been on osteonecrosis of the jaw and atypical femur fractures which occur in patients who have not received bisphosphonate therapy but may be more frequent (though still uncommon) in patients who have been on treatment for 5 years or longer. Lower-risk patients may be able to stop treatment after 3-5 years for a “drug holiday,” which mitigates these long-term risks; for higher risk patients, therapy through 6-10 years appears to be advisable and offers more benefits than risks.

scholarly journals Long-Term Alendronate Use Not without Consequences?

2009 ◽  
Vol 2009 ◽  
pp. 1-6 ◽  
Author(s):  
M. P. Somford ◽  
G. F. A. E. Geurts ◽  
J. W. A. M. den Teuling ◽  
B. J. W. Thomassen ◽  
W. F. Draijer
Keyword(s):  
Patient Group ◽  
Stress Fracture ◽  
Side Effect ◽  
Femur Fracture ◽  
Bisphosphonate Therapy ◽  
Lateral Side ◽  
Cortical Thickening ◽  
Specific Patient ◽  
Femur Fractures

A previously unknown side effect of biphosphonate use is emerging. In a specific patient group on long term biphosphonate therapy stress femur fractures seem to occur. The typical presentation consists of prodromal pain in the affected leg and/or a discrete cortical thickening on the lateral side of the femur in conventional radiological examination or the presentation with a spontaneous transverse subtrochanteric femur with typical features. We present three cases of this stress fracture in patients on bisphosphonate therapy. One of these patients suffered a bilateral femur fracture of the same type. In our opinion, in patients on bisphosphonate therapy who present with a spontaneous femur fracture, seizing therapy is advisable. In bilateral cases preventive nailing should be considered.

Atypical Femur Fracture in the Setting of Long-Term Bisphosphonate use for Osteogenesis Imperfecta: A Case Report

2022 ◽  
Vol 5 (1) ◽  
pp. 01-09
Author(s):  
Parker J. Prusick ◽  
Steven D. Jones Jr. ◽  
Jesse Roberts ◽  
Nathan Donaldson
Keyword(s):  
Case Report ◽  
Osteogenesis Imperfecta ◽  
Femur Fracture ◽  
Mineral Density ◽  
Mineral Research ◽  
Femur Fractures ◽  
Atypical Femur Fractures ◽  
Impending Fracture

Bisphosphonate (BP) therapy for moderate to severe osteogenesis imperfecta (OI) has become a mainstay of treatment in the last three decades. Given the significant improvements in bone mineral density and theoretical reductions in fracture risk, many patients are treated with bisphosphonates for prolonged periods of time. There currently lacks consensus in the optimal duration of BP therapy for patients with OI, and patients are often treated on a case-by-case basis. Long-term BP therapy has been associated with atypical femur fractures in adult patients treated for osteoporosis. The American Society for Bone and Mineral Research concluded that the median duration of BP therapy in patients with atypical femur fractures was 7 years. The role of long-term BP therapy in OI patients with atypical femur fractures remains unclear. Here, a case report is presented of an adolescent patient with type V OI that sustained a subtrochanteric femur fracture with features of an atypical pattern following treatment with intravenous pamidronate for 10.5 years. At the time of injury, the contralateral femur was also found to have atypical features suggestive of an impending fracture. The completed fracture was treated with closed reduction and cephalomedullary nail fixation. The impending fracture was prophylactically stabilized using the same technique. Prior to the injury, limb-length radiographs obtained to evaluate lower extremity alignment demonstrated features of an impending fracture but went unnoticed. Further studies are needed to clarify the role of long-term BP therapy in patients with OI suffering from atypical femur fractures.

scholarly journals Correction to: Treatment strategy for atypical ulnar fracture due to severely suppressed bone turnover caused by long-term bisphosphonate therapy: a case report and literature review

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Kensaku Abe ◽  
Hiroaki Kimura ◽  
Norio Yamamoto ◽  
Shingo Shimozaki ◽  
Takashi Higuchi ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Bone Turnover ◽  
Treatment Strategy ◽  
Bisphosphonate Therapy ◽  
Ulnar Fracture ◽  
Severely Suppressed Bone Turnover

An amendment to this paper has been published and can be accessed via the original article.

scholarly journals A Case Report of Long-Term Bisphosphonate Therapy and Atypical Stress Fracture of Bilateral Femur

2013 ◽  
Vol 37 (3) ◽  
pp. 430 ◽  
Author(s):  
Yil Ryun Jo ◽  
Hye Won Kim ◽  
Seock Ho Moon ◽  
Young Jin Ko
Keyword(s):  
Case Report ◽  
Stress Fracture ◽  
Bisphosphonate Therapy

scholarly journals Zoledronate-induced acute anterior uveitis: a three-case report and brief review of literature

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Xue Jin ◽  
Zhangxuan Shou ◽  
Yuhong Shao ◽  
Pingda Bian
Keyword(s):  
Case Report ◽  
Anterior Uveitis ◽  
Vision Loss ◽  
Bisphosphonate Therapy ◽  
Phase Reaction ◽  
Acute Anterior Uveitis ◽  
Blurred Vision ◽  
Treatment Regimens ◽  
Keratic Precipitates

Abstract Purpose This three-case report aims to highlight the ocular adverse effects induced by bisphosphonate therapy and to call clinicians’ attention. Methods Three cases of acute anterior uveitis secondary to the initial dose of zoledronate infusion were reported with focus on their symptoms, treatment regimens, and outcomes. A review of published reports provided a basis for discussion. Results Three cases of acute anterior uveitis were either bilateral or unilateral. They demonstrated typical manifestations of bisphosphonate-induced acute anterior uveitis such as eye pain, blurred vision, conjunctival and ciliary hyperemia, keratic precipitates, and flare in the anterior chamber. After topical corticosteroid-containing comprehensive treatments, these symptoms resolved completely without any vision loss and long-term sequelae. Conclusions Acute anterior uveitis may be part of the acute phase reaction induced by zoledronate. Patients should be informed of its symptoms in advance and be monitored closely during and after administration. Clinicians should have a good awareness of the zoledronate-associated acute anterior uveitis and to treat it in a prompt and appropriate manner.

Long-term side effects following pneumonectomy: A case report and review of the literature

2019 ◽  
Author(s):  
BA Högerle ◽  
EL Bulut ◽  
L Klotz ◽  
F Eichhorn ◽  
M Eichhorn ◽  
...  
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Review Of The Literature
Sign in / Sign up

Export Citation Format

Share Document